 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| Company |
Board of Directors
Peter Verhaeghe, Chairman, Attorney - LLM. Harvard, Belgium
Erik Buntinx, Managing Director, CEO / CSO, Belgium
Brian Elliott, Co-Founder, Ireland
Roger M. Pinder, Ph.D., D.Sc., former Head of CNS, Organon,
President of the International Society of Affective Disorders
(ISAD), UK.
Jo Breesh, Investment Director, KBC Private Equity, Belgium
Emmanuel Damman, Investment Manager, KBC Private Equity,
Belgium
Jos Sluys, CEO Saffelberg Investments
Rudi Mariën, CEO Biovest
Peter Verhaeghe, Chairman, Attorney - LLM. Harvard, Belgium
Erik Buntinx, Managing Director, CEO / CSO, Belgium
Brian Elliott, Co-Founder, Ireland
Roger M. Pinder, Ph.D., D.Sc., former Head of CNS, Organon,
President of the International Society of Affective Disorders
(ISAD), UK.
Jo Breesh, Investment Director, KBC Private Equity, Belgium
Emmanuel Damman, Investment Manager, KBC Private Equity,
Belgium
Jos Sluys, CEO Saffelberg Investments
Rudi Mariën, CEO Biovest
| © PharmaNeuroBoost 2012 - All Rights Reserved |
|  |  |  |  |  |  |  |  |
Publications
| News Highlights |
April 2nd, 2012
PharmaNeuroBoost
invited to present the
novel pharmacological
concept of its clinical
stage antipsychotic
PNB02 at the high
level CNS meeting
NCDEU in Phoenix,
USA, on May 29th
2012.
September 30th, 2011
First Patients Enrolled
in the PNB01 Phase III
clinical develop- ment
program in Major
Depression
PharmaNeuroBoost
invited to present the
novel pharmacological
concept of its clinical
stage antipsychotic
PNB02 at the high
level CNS meeting
NCDEU in Phoenix,
USA, on May 29th
2012.
September 30th, 2011
First Patients Enrolled
in the PNB01 Phase III
clinical develop- ment
program in Major
Depression